ReviewAdvances in experimental medicine and biology2026
Influence of RNA Modifications on Cancer Metabolism: Interplay with Hypoxia and Therapeutic Implications.
Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic reprogramming is a well-established hallmark of cancer, with tumors often altering glucose and lipid metabolism to fuel their rapid growth and survival. Hypoxia, a common feature of the tumor microenvironment, exacerbates these metabolic shifts by the stabilization of hypoxia-inducible factors (HIFs), which drive the Warburg effect, enhancing tumor aggressiveness. Recent research has unveiled a critical link between hypoxia and epitranscriptomic modifications, particularly m6A methylation, which further influences cancer metabolism and progression. This review explores the complex relationship between hypoxia-induced epitranscriptomic alterations and cancer metabolic reprogramming, focusing on m6A RNA methylation. By exploring how these mechanisms interact to regulate glucose and lipid metabolism, we highlight potential therapeutic targets that could be exploited to disrupt the metabolic dependencies of tumors and improve treatment outcomes for hypoxia-induced malignancies.
Indexed as
Identifiers
42435175What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.